VOR RSI Chart
Last 7 days
5.9%
Last 30 days
4.6%
Last 90 days
-12.1%
Trailing 12 Months
-58.4%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 06, 2024 | chakraborty tirtha | sold (taxes) | -1,531 | 1.75 | -875 | chief scientific officer |
May 06, 2024 | ang robert | sold (taxes) | -4,131 | 1.75 | -2,361 | president and ceo |
May 06, 2024 | attar eyal c. | sold (taxes) | -1,748 | 1.75 | -999 | chief medical officer |
May 06, 2024 | jorgensen nathan d. | sold (taxes) | -1,459 | 1.75 | -834 | chief financial officer |
May 01, 2024 | ang robert | sold (taxes) | -4,869 | 1.77 | -2,751 | president and ceo |
May 01, 2024 | jorgensen nathan d. | sold (taxes) | -1,623 | 1.77 | -917 | chief financial officer |
May 01, 2024 | chakraborty tirtha | sold (taxes) | -1,743 | 1.77 | -985 | chief scientific officer |
May 01, 2024 | attar eyal c. | sold (taxes) | -2,028 | 1.77 | -1,146 | chief medical officer |
Mar 01, 2024 | jorgensen nathan d. | sold (taxes) | -14,323 | 2.27 | -6,310 | chief financial officer |
Mar 01, 2024 | chakraborty tirtha | sold (taxes) | -12,657 | 2.27 | -5,576 | chief scientific officer |
Which funds bought or sold VOR recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Artal Group S.A. | reduced | -57.4 | -2,912,000 | 2,370,000 | 0.06% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.12 | -4,858 | 9,094 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | added | 15.03 | 8,070 | 46,196 | -% |
May 16, 2024 | COMERICA BANK | new | - | 6,307 | 6,307 | -% |
May 15, 2024 | LMR Partners LLP | reduced | -19.98 | -18,074 | 96,926 | -% |
May 15, 2024 | STATE STREET CORP | added | 8.17 | 190,750 | 1,558,770 | -% |
May 15, 2024 | RA CAPITAL MANAGEMENT, L.P. | unchanged | - | 2,729,870 | 53,914,800 | 0.69% |
May 15, 2024 | DEUTSCHE BANK AG\ | unchanged | - | 3,820 | 75,449 | -% |
May 15, 2024 | MORGAN STANLEY | reduced | -26.37 | -86,876 | 300,261 | -% |
May 15, 2024 | HSBC HOLDINGS PLC | new | - | 41,961 | 41,961 | -% |
Unveiling Vor Biopharma Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Vor Biopharma Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Vor Biopharma Inc. News
Balance Sheet | |||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | -15.7% | 167 | 198 | 223 | 251 | 278 | 299 | 206 | 225 | 234 | 243 | 259 | 275 | 293 | 76.00 |
Current Assets | -20.6% | 112 | 141 | 164 | 191 | 217 | 237 | 143 | 159 | 190 | 214 | 232 | 249 | 266 | 49.00 |
Cash Equivalents | 43.4% | 45.00 | 31.00 | 45.00 | 32.00 | 42.00 | 58.00 | 61.00 | 63.00 | 90.00 | 120 | 143 | 170 | 263 | 49.00 |
Net PPE | -8.8% | 9.00 | 10.00 | 11.00 | 11.00 | 12.00 | 13.00 | 13.00 | 15.00 | 12.00 | 7.00 | 6.00 | 6.00 | 6.00 | 5.00 |
Liabilities | -7.2% | 44.00 | 47.00 | 48.00 | 47.00 | 47.00 | 49.00 | 48.00 | 50.00 | 40.00 | 26.00 | 26.00 | 25.00 | 26.00 | 28.00 |
Current Liabilities | -15.1% | 13.00 | 16.00 | 15.00 | 13.00 | 13.00 | 13.00 | 11.00 | 12.00 | 18.00 | 10.00 | 9.00 | 8.00 | 9.00 | 10.00 |
Shareholder's Equity | -18.4% | 123 | 151 | 175 | 204 | 230 | 251 | 159 | 175 | 194 | 216 | 233 | 250 | 267 | - |
Retained Earnings | -9.1% | -370 | -340 | -313 | -280 | -250 | -222 | -198 | -174 | -152 | -130 | -111 | -93.32 | -74.95 | -61.22 |
Additional Paid-In Capital | 0.6% | 494 | 491 | 489 | 486 | 481 | 474 | 358 | 351 | 348 | 346 | 345 | 343 | 342 | 2.00 |
Shares Outstanding | 0.5% | 68.00 | 68.00 | 68.00 | 67.00 | 67.00 | 66.00 | 38.00 | 37.00 | 37.00 | 37.00 | 32.00 | 37.00 | - | - |
Float | - | - | - | - | 136 | - | - | - | 116 | - | - | - | 352 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Cashflow From Operations | -26.8% | -30,465 | -24,026 | -27,898 | -24,100 | -24,268 | -18,346 | -18,902 | -24,992 | -22,904 | -17,587 | -17,343 | -16,565 | -17,649 | -13,634 | -8,245 | -8,328 | -6,085 |
Share Based Compensation | 62.7% | 3,081 | 1,894 | 3,162 | 4,238 | 4,068 | 3,879 | 3,329 | 1,741 | 1,746 | 1,203 | 1,154 | 1,067 | 891 | 594 | 483 | 153 | 112 |
Cashflow From Investing | 325.5% | 43,973 | 10,335 | 40,536 | 13,639 | 6,498 | -97,036 | 12,702 | -2,702 | -7,055 | -5,953 | -8,486 | -76,041 | -1,171 | -1,477 | -1,587 | -552 | -545 |
Cashflow From Financing | 284.0% | 96.00 | 25.00 | 176 | 218 | 2,519 | 112,261 | 4,075 | 604 | 200 | 307 | 201 | -445 | 232,848 | 46.00 | 526 | 64,192 | 17,762 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 24,322 | $ 21,915 |
General and administrative | 8,004 | 8,507 |
Total operating expenses | 32,326 | 30,422 |
Loss from operations | (32,326) | (30,422) |
Other income: | ||
Interest income | 1,522 | 1,989 |
Total other income | 1,522 | 1,989 |
Net loss | $ (30,804) | $ (28,433) |
Net loss per share attributable to common stockholders, basic | $ (0.45) | $ (0.43) |
Net loss per share attributable to common stockholders, diluted | $ (0.45) | $ (0.43) |
Weighted-average common shares outstanding, basic | 68,030,966 | 66,265,703 |
Weighted-average common shares outstanding, diluted | 68,030,966 | 66,265,703 |
Other comprehensive income (loss): | ||
Unrealized (loss) gain on available for sale marketable securities | $ (10) | $ 596 |
Total other comprehensive (loss) income | (10) | 596 |
Comprehensive loss | $ (30,814) | $ (27,837) |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 44,964 | $ 31,360 |
Marketable securities | 62,515 | 105,815 |
Prepaid expenses | 3,831 | 3,153 |
Other current assets | 507 | 475 |
Total current assets | 111,817 | 140,803 |
Restricted cash equivalents | 2,413 | 2,413 |
Property and equipment, net | 9,165 | 10,050 |
Operating lease right-of-use assets | 38,816 | 40,048 |
Other assets | 4,819 | 4,812 |
Total assets | 167,030 | 198,126 |
Current liabilities: | ||
Accounts payable | 2,325 | 815 |
Accrued liabilities | 6,797 | 10,877 |
Operating lease liabilities | 3,957 | 3,830 |
Other current liabilities | 134 | 50 |
Total current liabilities | 13,213 | 15,572 |
Long-term liabilities: | ||
Operating lease liabilities—non-current | 30,782 | 31,830 |
Total liabilities | 43,995 | 47,402 |
Stockholders' equity: | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | ||
Common stock, $0.0001 par value; 400,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 68,223,496 and 67,901,610 shares issued and 68,215,771 and 67,891,311 outstanding as of March 31, 2024 and December 31, 2023, respectively | 7 | 7 |
Additional paid-in capital | 493,999 | 490,874 |
Accumulated other comprehensive loss | (87) | (77) |
Accumulated deficit | (370,884) | (340,080) |
Total stockholders' equity | 123,035 | 150,724 |
Total liabilities and stockholders' equity | $ 167,030 | $ 198,126 |